aimei Technology of Shanghai completed a $176 million financing to support its AI cloud-based suite of programs for clinical trials. The company says its SAAS platform enables clinical research collaboration between sponsors, sites, CROs, patients, regulatory agencies and third-party providers. Its latest funding was co-led by Tencent Holdings, GL Ventures (a Hillhouse subsidiary) and YF Capital. One year ago, Taimei closed a $212 million Series E/E+ round. More details.... Share this with colleagues: // //